Track Viridian Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Viridian Therapeutics, Inc. VRDN · Stock Open Viridian Therapeutics, Inc. in new tab

30.90 USD
EPS
-3.85
P/B
7.26
ROE
-83.71
Beta
1.07
Target Price
41.69 USD
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-3.85
Book Value4.25
Price to Book7.26
Debt/Equity42.28
% Insiders0.169%
Growth
Revenue Growth-0.64%
Estimates
Forward P/E-14.48
Forward EPS-2.13
Target Mean Price41.69

DCF valuation

Model fair value for Viridian Therapeutics, Inc. (VRDN)
Result
Sign in to run the valuation for VRDN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
16 analysts · consensus Strong buy · mean target 41.69 USD (low 33.00, high 54.00) · as of 10 Nov 2026
Low 33.00
Mean 41.69
High 54.00
Price 30.90
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Viridian Therapeutics, Inc. Logo Viridian Therapeutics, Inc. Analysis (VRDN)

United States Health Care Official Website Stock

Is Viridian Therapeutics, Inc. a good investment? Viridian Therapeutics, Inc. (VRDN) is currently trading at 30.90 USD. Market analysts have a consensus price target of 41.69 USD. This suggests a potential upside from current levels.

Earnings Schedule: Viridian Therapeutics, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -2.13.

Investor FAQ

Does Viridian Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Viridian Therapeutics, Inc.?

Viridian Therapeutics, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -3.85.

Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) VRDN
FRA (Germany) 1S1.F
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 7, 2016 1:15
Nov. 13, 2020 1:15
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion